Enhancing tumor radiosensitivity by intracellular delivery of survivin antagonists

Medical Hypotheses

Volumn 68, Issue 5, 2007, Pages 1056-1058

  Shi, Mei ^a   Guo, Xiao Tong ^a   Shu, Mao Guo ^a   Li, Li Wen ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; RADIOSENSITIZING AGENT; SURVIVIN; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CELL MEMBRANE; CELL SURVIVAL; CORRELATION ANALYSIS; ENDOTHELIUM CELL; IRRADIATION; MAMMAL CELL; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR CELL; UPREGULATION;

GENE THERAPY; GENETIC VECTORS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; RADIATION TOLERANCE; RNA INTERFERENCE; TRANSFECTION;

MAMMALIA;

EID: 33847021164     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.09.048     Document Type: Article

References (19)

1. Wheatley S.P., and McNeish I.A. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247 (2005) 35-88
2. Zaffaroni N., Pennati M., and Daidone M.G. Survivin as a target for new anticancer interventions. J Cell Mol Med 9 2 (2005) 360-372
3. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92 2 (2005) 212-216
4. Kami K., Doi R., Koizumi M., et al. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 138 2 (2005) 299-305
5. McLaughlin N., Annabi B., Bouzeghrane M., et al. The survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate. Brain Res 1071 1 (2006) 1-9
6. Rodel F., Hoffmann J., Distel L., et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65 11 (2005) 4881-4887
7. Cao C., Mu Y., Hallahan D.E., and Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23 42 (2004) 7047-7052
8. Lu B., Mu Y., Cao C., et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 64 8 (2004) 2840-2845
9. Asanuma K., Kobayashi D., Furuya D., Tsuji N., Yagihashi A., and Watanabe N. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 93 9 (2002) 1057-1062
10. Asanuma K., Moriai R., Yajima T., et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91 11 (2000) 1204-1209
11. Kappler M., Taubert H., Bartel F., et al. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 13 1 (2005) 167-172
12. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 5622 (2003) 1155-1159
13. Fuks Z., and Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 8 2 (2005) 89-91
14. Zhu D.E., Hoti N., Song Z., et al. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene survivin-D53A in a nude mice model. Cancer Gene Ther 13 8 (2006) 762-770
15. Cao L., Yan X., Wu Y., et al. Survivin mutant (Surv-DD70, 71AA) disrupts the interaction of survivin with Aurora B and causes multinucleation in HeLa cells. Biochem Biophys Res Commun 346 2 (2006) 400-407
16. Zhang M., Mukherjee N., Bermudez R.S., et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 64 3 (2005) 293-302
17. Tu S.P., Cui J.T., Liston P., et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 128 2 (2005) 361-375
18. McKay T.R., Bell S., Tenev T., et al. Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. Oncogene 22 23 (2003) 3539-3547
19. Yan H, Thomas J, Liu T, et al. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. Oncogene, in press, doi:10.1038/sj.onc.1209676.